Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah this is crazy…. Let’s take a closer look:
12/29/23 the judge says “you need to prove loss causation. Everything else looks good.”
1/20/24 posner points out things overlooked by the judge in their filing and cites a few pages but does not supply any further evidence of loss causation.
2/14/24: judge says. You didn’t provide any further evidence of loss causation. MTD granted without prejudice. You have 30 days to restart this train.
Glad Posner took this on contingency…. Unreal.
I know I know, just focus on approvals. I’m trying…. But had my hopes up for a better lawsuit outcome.
Exactly… I see he sold before the PR. I’m questioning if he bought his shares back today?… link. 12/1/23.
https://stocktwits.com/JonnyShooter/message/553064648
Wait did he sell them before the last PR and then buy them back today?
https://stocktwits.com/JonnyShooter/message/553064648
Interesting.
Thermo,
You hearing anything? I am still of the belief that the August 29 PR only happened because you mentioned that you requested to management that they give us a timeline/more information.
Boston Red Sox former pitching great Tim Wakefield dies of brain cancer.
The Red Sox post on social media “our hearts are broken”
Little does everybody know the Boston Red Sox owner (John Henry) is owner and cofounder of Stat News.
I’m not joking.
https://apple.news/Ak1VEKetBTUW7Qw31fED23Q
https://www.mlb.com/news/tim-wakefield-dies-at-57
Legend 341,
Thermo gave proof of a few of his warrants a few years back. In fact, I think it was during an exchange with LC….. lol. See below:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160353814
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160353826
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160353843
Thermo, Ok. Thank you. I’m just trying to keep everything straight. Your posts carry the most weight around here it seems.
Thermo,
On May 12 you said you had no insight on the 3 million.
Now, it was you after all?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171894974
Has this been discussed yet?
https://www.uclahealth.org/news/new-drug-delays-progression-glioma-deadly-brain-cancer
I’m not sure I understand your reply. He post a trial involving dcvax-L with combos.
The article is still up under "see all latest news" on the braintumorresearch.org website. It does not appear to be taken down.
Link: https://www.braintumourresearch.org/media/news/news-item/2023/03/29/significant-regulation-overhaul-sees-clinical-trial-approvals-streamlined
Notes from presentation today:
1- I couldn't help but note that Matthias Preusser presented right before Dr. Liau. He was one of the physicians to write an article slamming the Phase 3 results presented in Jama. There was no interaction between he and Dr. Liau.
2. It was about 8-9 mins long. She moved very quickly. She basically gave an overview of the study criteria and discussed the issues with progression free survival. She specifically noted they changed the endpoints and developed the SAP prior to being unblinded. This was important to note as this seems to be unclear to naysayers including the aformentioned Preusser.
3. She seemed upbeat and proud of the results.
4. There was a "limitations" page to her presentation. She specifically noted this unfortunately was not a radomnly controlled trial (RCT) however...she noted "this does not mean the results are not valid. It just means this is a lower level of evidence than an RCT." She spoke on how she hopes this trial leads to more sponsers of trials to release patient level data from past trials so more external controls can be formulated and "less patients in trials need to undergo the standard of care."
5. Her last page was about combination therapies. I vaguely remember she lead off this slide.."and possibly most exciting " the potential for combinations therapies ....and went into DCVax-L getting T-cells going ect.
I hope this helps. Not comprehensive but...just shooting down some thoughts from memory.
THANK YOU to all of our wonderful longs who provided a countless bits of good information, positive thoughts, reassurance, and solid knowledge. A lot of you truly amaze me!
Gary,
Sunday 11/20
Click on the down arrow/drop menu on the 7:50 Plenary Session.
She is the second session. Right after Dr Mitchell from the University of Florida.
It’s there buddy.
Hey Flip or Thermo or Senti et al,
Did our trial show a good response rate?
“In oncology, the efficacy end point most frequently used for AA is a durable overall response rate. This rate is a reliable marker of drug activity, since malignant tumors generally do not shrink without therapeutic intervention.”
Today’s NEJM….. Pazsur one of the authors.
https://www.nejm.org/doi/full/10.1056/NEJMp2208954?query=featured_home
#ithinkwegotthis
Not true. They are a helmet ally…. It’s well documented here in previous posts.
Bright Boy,
Thanks for posting. You note that you expect the c shares to be reserved for a potential partner. I hope that is the case but it appears iwasadiver has been posting his communication with the company and his intent to buy some as an individual investor.
Thoughts?
Ae kusterer,
What is making you reverse course?…
Thanks in advance for your response.
Wimike,
Below is a link the trial. Merk still listed. Stay calm buddy.
https://clinicaltrials.gov/ct2/show/NCT04201873?term=Pembrolizumab+and+a+Vaccine+%28ATL-DC%29+for+the+Treatment+of+Surgically+Accessible+Recurrent+Glioblastoma&draw=2&rank=1
Pedes,
Here is a link to the clinicaltrials.org website which clearly shows that you providing inaccurate information.
https://clinicaltrials.gov/ct2/show/NCT04201873?term=Pembrolizumab+and+a+Vaccine+%28ATL-DC%29+for+the+Treatment+of+Surgically+Accessible+Recurrent+Glioblastoma&draw=2&rank=1
I wish you well but hope you decrease your efforts in providing FUD.
Sojo,
I tend to read a lot of yours and Judge's posts. How do you feel about the big red cloud he mentioned recently that is coming.
Hope all is well.
U Penn
https://www.pennmedicine.org/for-health-care-professionals/for-physicians/physician-education-and-resources/provider-events?trumbaEmbed=view%3Devent%26eventid%3D159057721
I think this might be the talk Dr. Brem mentioned on May 10th.
LEARNING OBJECTIVES Upon completion of this conference, participants should be able to:
Implement COVID 19 disease prevention policies for cancer patients
List changes in cancer management for patients affected by COVID 19
***Identify recent advances in immunotherapy for cancer treatment
***Implement new clinical findings to a broad range of tumor types
Identify issues related to extent of therapy by genomics, stage and patient condition
“Coerced not to speak by nefarious forces”
Sarcasm?…orsupposed threats?….if not those could you please elaborate?
Well….. shit. Thanks for the response.
Judge… why do you feel that is the case? I’m asking you because you usually aren’t cavalier with negativity.
Thermo!….as in. Journal of American Medical Association?
Thermo… full reasons?…. Was it more than her getting Covid-19? Please elaborate if you can.
I don’t know if the threatening letters thing is validated or not. Was it something else?
Emails like this will carry more weight once the clinical trials.gov is updated with the new endpoints. I too will send an email to them this weeks with the link to clinicaltirls.gov website once it is updated.
FeMike,
I’ve been waiting to read something like this. So thank you! This is a really important post I think most should read. Something just didn’t fit….about their argument. Now we know.
Dr. Bala and FeMike,
This is a great conversation. Thank you both.
Dr. Bala,
Thanks for your thoughts and the reply.
Nix,
Thanks for the post. I do think the biggest short argument right now is that the mOS survival of the blended data was better than the final data with control patients taken out.. Thoughts on this?
Thermo: Thoughts?
Hoffman,
Fair enough. Thanks for the reply.
Hoffman,
Wouldn’t Dr. Ashkan be our #1 backup?
So far we have “ definitely TLD data tomorrow”….”DI told me data will be released tomorrow”… “DI told my dad data will be released tomorrow”…. And AF tweeting “no data tomorrow; never even planned to have data tomorrow.”
Mother of God
DD,
You still think tomorrow happens without Dr. Liau?
Next Annals of Oncology due out May12th
https://www.elsevier.com/journals/personal/annals-of-oncology/0923-7534?dgcid=SD_ecom_referral_journals
This really may be it!
ASCO
Industry Expert Theatre
Saturday June 4th
Time: 3:00 PM–4:00 PM
Title: Dendritic Cell Vaccines for Cancer
Description: The rapid development and rollout of COVID vaccines have led to increased interest in other vaccines, including for cancer. Also, growing knowledge of tumor biology and heterogeneity is increasing the interest in personalized treatments. We will discuss personalized dendritic cell cancer vaccines.
Company: Northwest Biotherapeutics, Inc.
Presenter: Marnix Bosch, PhD, Chief Technical Officer, Northwest Biosciences
https://conferences.asco.org/am/industry-expert-theater
Wait… I was under the impression that doc noted the fact that the last 17patients not being enrolled was a good thing….
Now ex is stating that the fda did not let the last patients enroll?…which is it?